Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent vascular thrombosis and pregnancy losses. Laboratory diagnosis of APS relies on the demonstration of a positive anticardiolipin antibody test by an in-house or commercially available enzyme-linked immunosorbent assay, or on the presence of lupus anticoagulant by a coagulation-based test. Persistence of the positive results must be demonstrated, and other causes and underlying factors considered. Although it is universally recognized that the routine screening tests (anticardiolipin antibody or lupus anticoagulant) might miss some cases of APS, careful differential diagnosis and repeat testing are mandatory before the diagnosis of 'seronegative APS' can be made. Correct identification of patients with APS is important because prophylactic anticoagulant therapy can prevent thrombosis from recurring and treatment of affected women during pregnancy can improve fetal and maternal outcome.
Key Points
-
Antiphospholipid syndrome (APS) is the most common acquired thrombophilia
-
Venous and arterial thrombosis in young individuals, and pregnancy morbidity, are the hallmarks of the disease
-
In the clinical setting, testing for both anticardiolipin antibodies and lupus anticoagulant is essential for the diagnosis of APS
-
Differential diagnoses must be considered before labelling a patient as having 'seronegative APS'
-
Correct identification of patients with APS is important, because prophylactic anticoagulant therapy can prevent thrombosis from recurring
-
Treatment of affected women during pregnancy can improve fetal and maternal outcomes
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hughes GRV (1983) Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 287: 1088–1089
Wilson WA et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309–1311
Asherson RA et al. (1989) The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68: 366–374
Vianna JL et al. (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 96: 3–9
Finazzi G et al. (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 100: 530–536
Krnic-Barrie S et al. (1997) A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 157: 2101–2108
Godfrey T and D'Cruz D (2000) Antiphospholipid syndrome: general features. In Hughes syndrome, 8–19 (Ed Khamashta MA) London: Springer-Verlag
Khamashta MA et al. (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993–997
Branch DW and Khamashta MA (2003) Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol 101: 1333–1344
Wasserman A et al. (1906) Eine serodiagnostische reaktion bei syphilis. Dtsch Med Wochenschr 32: 745–746
Pangborn MC (1941) A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 48: 484–486
Haserick JR and Long R (1952) Systemic lupus erythematosus preceded by false-positive serologic test for syphilis: presentation of five cases. Ann Intern Med 37: 559–565
Harris EN et al. (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2: 1211–1214
Blank M et al. (1991) Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 88: 3069–3073
Pierangeli SS et al. (1995) Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 74: 1361–1367
Pierangeli SS and Harris EN (1997) In vivo models for thrombosis for the antiphospholipid syndrome. Lupus 5: 451–455
Del Papa N et al. (1997) Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40: 551–561
Reverter JC et al. (1998) Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 41: 1420–1427
Campbell AL et al. (1995) Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73: 529–534
Smirnov MD et al. (1995) On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 95: 309–316
Holers VM et al. (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195: 211–220
Girardi G et al. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112: 1644–1654
Cervera R et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46: 1019–1027
Shah NM et al. (1998) Outcome of patients with anticardiolipin antibodies: a 10-year follow-up of 52 patients. Lupus 7: 3–6
Levine SR et al. (1990) Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40: 1181–1189
Brey RL et al. (1990) Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 40: 1190–1196
The Antiphospholipid Antibodies in Stroke Study (APASS) Group (1993) Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43: 2069–2073
Camerlingo M et al. (1995) Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 92: 69–71
Levine SR et al. (1995) Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 38: 119–124
Brey RL et al. (2001) Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 32: 1701–1706
Montalban J et al. (1994) Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke 25: 2412–2415
Ginsburg KS et al. (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117: 997–1002
The Antiphospholipid Antibodies in Stroke Study (APASS) Group (1997) Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48: 91–94
Carhuapoma JR et al. (1997) Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28: 2363–2369
Deschiens MA et al. (1996) Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27: 1724–1730
Ijdo JW et al. (1999) Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus 8: 109–115
Cuadrado MJ et al. (2000) Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 79: 57–68
Nochy D et al. (1999) The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10: 507–518
Sangle SR et al. (2003) Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 62: 999–1002
Branch DW et al. (1985) Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313: 1322–1326
Lockshin MD et al. (1985) Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 313: 152–156
Branch DW et al. (1992) Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80: 614–620
Caruso A et al. (1993) Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol 82: 970–977
Lima F et al. (1996) A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14: 131–136
Duckitt K and Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330: 565
Lockshin MD et al. (2000) Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 43: 440–443
Mouritsen S et al. (1989) The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus. Clin Exp Immunol 76: 178–183
Harris EN et al. (1988) Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis 157: 23–31
Galvez J et al. (1997) Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies. Med Clin (Barc) 108: 396–397
Intrator L et al. (1988) Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura. Br J Haematol 68: 269–270
Schulman S et al. (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104: 332–338
Escalante A et al. (1995) Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 98: 559–565
Levine SR et al. (1997) IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28: 1660–1665
Matsuura E et al. (1994) Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179: 457–462
Amengual O et al. (1996) Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 35: 1239–1243
Cabral AR et al. (1996) The antiphospholipid/cofactor syndrome: a primary variant with antibodies to b2 glycoprotein I but no antibodies detectable in standard antiphospholipid assay. Am J Med 101: 472–481
Levine JS et al. (2002) The antiphospholipid syndrome. N Engl J Med 346: 752–63
Hughes GR (2003) Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 79: 81–83
Brandt JT et al. (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 74: 1185–1190
Greaves M et al. (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109: 704–715
Pengo V et al. (1987) Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70: 69–76
Galli M et al. (1993) Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 83: 466–472
Triplett DA et al. (1988) The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 259: 550–554
McNeil HP et al. (1989) Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 73: 506–513
Wahl DG et al. (1997) Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. Lupus 6: 467–473
Wahl DG et al. (1998) Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 7: 15–22
Somers E et al. (2002) Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29: 2531–2536
Galli M et al. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827–1832
Galli M et al. (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102: 2717–2723
Hughes GR and Khamashta MA (2003) Seronegative antiphospholipid syndrome. Ann Rheum Dis 62: 1127
Bertolaccini ML et al. (2001) The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 28: 2637–2643
Molina JF et al. (1997) Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 24: 291–296
Diri E et al. (1999) Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 8: 263–268
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bertolaccini, M., Khamashta, M. & Hughes, G. Diagnosis of antiphospholipid syndrome. Nat Rev Rheumatol 1, 40–46 (2005). https://doi.org/10.1038/ncprheum0017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0017
This article is cited by
-
Antibodies to Serine Proteases in the Antiphospholipid Syndrome
Current Rheumatology Reports (2010)
-
Epidural hematoma mimicking transverse myelitis in a patient with primary antiphospholipid syndrome
Rheumatology International (2008)
-
Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons
Current Rheumatology Reports (2008)